12/21/2022Corporate
12/14/2022Products
JSR commercializes interface molecular bonding material with high adhesion New product can meet the need for high-speed communication infrastructure Expect use in further applications such as electric vehicles
12/13/2022Corporate
Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
12/05/2022Corporate
JSR at SEMICON Japan 2022
12/02/2022Corporate
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevant Oncology Drug Development
11/17/2022Sustainability
JSR Group Releases its “JSR Group Sustainability Site 2022”
11/10/2022Information
Tim Lowery Appointed Interim CEO of KBI and Selexis
11/02/2022Corporate
JSR Joins Semiconductor Climate Consortium as Founding Member
10/26/2022Corporate
JSR Life Sciences, LLC signs development and license agreement with Blau Farmacêutica
10/13/2022Corporate
JSR Electronic Materials Korea to be a JSR Wholly Owned Subsidiary
10/03/2022Corporate
JSR Group started operation of a local subsidiary for Electronic Materials Business in China
09/27/2022Corporate
Crown Bioscience & MBL launch joint venture to serve Japanese biopharmaceutical community
09/27/2022Products
Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media Business
09/22/2022Information
JSR Issues JSR Report 2022 in English
09/22/2022Products
MBL Obtained manufacturing and marketing approval a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens
09/16/2022Information
News about “Holter monitor Heartnote™"
09/01/2022Products
MBL obtained European Quality Management System Certificate (IVDR)
08/25/2022Corporate
JSR to Establish a New Subsidiary for Semiconductor Materials in China
08/08/2022Sustainability
JSR selected for the MSCI Japan ESG Select Leaders Index
08/02/2022Corporate
Inpria Co-Developing Metal Oxide Resist with SK hynix to Reduce Complexity of Patterning for Next-Generation DRAM
08/01/2022Products
MEBGEN™ BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma
07/29/2022Corporate
Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership
07/07/2022Corporate
KBI and Selexis Held an Opening Ceremony of New Manufacturing Facility in Geneva
07/05/2022Corporate
JSR Develops Highly Adhesive, Highly Dispersive Materials
06/28/2022Corporate
JSR at 5G Technology Expo
06/21/2022Corporate
JSR at SEMICON SEA 2022 | SEMICON Southeast Asia
06/15/2022Corporate
KBI and Selexis announced Completion of Expansion of Manufacturing Facility in Geneva
06/06/2022Corporate
JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Value Creation in the Microbiome
06/03/2022Corporate
JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.
05/12/2022Corporate
Medical & Biological Laboratories and Crown Bioscience Enter Joint Venture ~Providing Advanced Preclinical Services in Japan~
05/11/2022Corporate
JSR Life Sciences Launches ‘Similis Bio’ to Help Partners Accelerate Biosimilar Development
05/06/2022Corporate
Announcement of New CEO at KBI and Selexis
04/22/2022Corporate
KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility
04/04/2022Corporate
Launch of a New Kit for the Detection of anti-Integrin αvβ6 Antibodies (MBL)
03/23/2022Corporate
JSR to Establish a New Subsidiary for Semiconductor Materials in Taiwan
03/22/2022Corporate
In a World First, Yokogawa and JSR Use AI to Autonomously Control a Chemical Plant for 35 Consecutive Days
03/17/2022Corporate
KBI Biopharma Signed an Agreement with Oragenics to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV 2 -1
03/16/2022Products
JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
03/15/2022Corporate
JSR Expands the Shanghai Technical Center for Display Materials
03/14/2022Corporate
JSR enters into Contract R&D Agreement with AMED for Development of Basic Technologies for Next-Generation Therapeutics and Diagnostics
02/01/2022Corporate
Success in Highly Efficient Linking of Two Epoxides under Nonstoichiometric Condition
01/18/2022Corporate
Notice Regarding Share Transfer and Joint Venture Dissolution of Japan Fine Coatings Co., Ltd.
01/05/2022Corporate